ストックスクリーナーアプリを入手
97.38
1.65%
-1.64
前日終値:
$99.02
開ける：
$99.36
24時間の取引高:
332.45K
Relative Volume:
0.45
時価総額：
$6.71B
収益：
$217.17M
当期純損益:
$-202.68M
株価収益率:
-42.29
EPS:
-2.3028
ネットキャッシュフロー:
$-156.63M
1週間 パフォーマンス:
-6.99%
1か月 パフォーマンス:
-15.50%
6か月 パフォーマンス:
+13.43%
1年 パフォーマンス:
-1.17%
1日の値動き範囲:
$97.37
$99.36
1週間の範囲:
$96.14
$105.93
52週間の値動き範囲:
$74.50
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
名前
Rhythm Pharmaceuticals Inc
セクター
電話
857-264-4280
住所
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
97.41 | 7.21B | 217.17M | -202.68M | -156.63M | -2.3028 |
VRTX
Vertex Pharmaceuticals Inc
|
506.38 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.47 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
997.56 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
154.76 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
190.60 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-19 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-11-25 | 開始されました | Citigroup | Buy |
| 2025-11-05 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-07-10 | 開始されました | Goldman | Buy |
| 2025-07-07 | 開始されました | Leerink Partners | Outperform |
| 2025-04-07 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-03-05 | 再開されました | Stifel | Buy |
| 2025-01-02 | 開始されました | Jefferies | Buy |
| 2024-12-20 | 開始されました | Oppenheimer | Outperform |
| 2024-10-21 | 開始されました | Guggenheim | Buy |
| 2024-09-18 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-17 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-05-08 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-01-18 | 再開されました | Canaccord Genuity | Buy |
| 2022-08-08 | アップグレード | Goldman | Neutral → Buy |
| 2022-08-05 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-06-17 | 繰り返されました | Needham | Buy |
| 2022-03-02 | 再開されました | Stifel | Buy |
| 2022-02-17 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | 再開されました | Goldman | Neutral |
| 2021-08-04 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2021-08-04 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-01-08 | 開始されました | Goldman | Sell |
| 2019-07-12 | アップグレード | Stifel | Hold → Buy |
| 2019-07-08 | 開始されました | Canaccord Genuity | Buy |
| 2019-03-13 | 開始されました | Ladenburg Thalmann | Buy |
| 2018-09-07 | 再開されました | Morgan Stanley | Overweight |
| 2018-06-25 | 繰り返されました | Needham | Buy |
| 2018-06-15 | 繰り返されました | Needham | Buy |
| 2017-10-30 | 開始されました | BofA/Merrill | Buy |
| 2017-10-30 | 開始されました | Needham | Buy |
すべてを表示
Rhythm Pharmaceuticals Inc (RYTM) 最新ニュース
Avoiding Lag: Real-Time Signals in (RYTM) Movement - Stock Traders Daily
Obesity Market to Witness Strong Growth and Significant Market Expansion by 2036 – DelveInsight | Rhythm Pharma, Boehringer Ingelheim, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical - Barchart.com
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting - manilatimes.net
French children showed lower body-size scores on a rare-obesity drug - Stock Titan
Rhythm Pharmaceuticals at Wells Fargo conference: ho launch gains traction By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A 36.45% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
An AI drug specialist zeroes in on rare forms of obesity - BioPharma Dive
Here’s How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years - Benzinga
Rhythm Pharmaceuticals stock edges lower after insider sale but stays backed by strong Q2 growth - AD HOC NEWS
How Rhythm Pharmaceuticals Inc. (RYTM) Affects Rotational Strategy Timing - Stock Traders Daily
Rhythm Pharmaceuticals(RYTM.US) Officer Sells US$6.62 Million in Common Stock - Moomoo
Rhythm Pharmaceuticals (RYTM) CFO sells 62,774 shares in planned trade - Stock Titan
Rhythm (NASDAQ: RYTM) officer files Rule 144 stock sale notice - Stock Titan
Here's How Much $100 Invested In Rhythm Pharmaceuticals 5 Years Ago Would Be Worth Today - Benzinga
Rhythm Pharmaceuticals (RYTM): Investor Outlook on a 30.81% Potential Upside in Biotechnology - DirectorsTalk Interviews
Rhythm Pharmaceuticals Inc. (RYTM) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
RHYTHM PHARMACEUTICALS, INC. : DEUTSCHE BANK INITIATES COVERAGE WITH HOLD RATING AND TARGET PRICE $120 - webull.com
Deutsche Bank Initiates Rhythm Pharmaceuticals(RYTM.US) With Hold Rating, Announces Target Price $120 - Moomoo
Deutsche Bank Initiates Rhythm Pharmaceuticals at Hold With $120 Price Target - marketscreener.com
Rhythm Pharmaceuticals (RYTM) Could Be 15% Undervalued As Japan Approval Lifts Its Story - sahmcapital.com
Rhythm Pharmaceuticals Gains Japan Approval For IMCIVREE In Hypothalamic Obesity - DirectorsTalk Interviews
Rhythm Pharmaceuticals (RYTM) Stock Looks Overvalued Despite Its 7x Five Year Run - Yahoo Finance
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan - The Manila Times
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Biotechnology Innovator Seeks 28.67% Upside with Breakthrough Therapies - DirectorsTalk Interviews
Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can - Yahoo Finance
Blue Owl Capital Holdings LP Invests $6.82 Million in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
TD Cowen Names Rhythm Pharmaceuticals Its Top Pick Following Robust Q2 Results - StockInvest.us
Rhythm Pharmaceuticals (RYTM) grants CMO 50K options expiring 2036 - Stock Titan
Rhythm (RYTM) CMO reports no company stock holdings - Stock Titan
Rhythm Pharmaceuticals (RYTM) Stock Looks Pricey Following Strong IMCIVREE News - Sahm
Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer - Sahm
Rhythm Pharmaceuticals: Building A Defensive MC4R Franchise (NASDAQ:RYTM) - Seeking Alpha
Rhythm Pharmaceuticals CSO Alastair Garfield sells $912,703 in stock By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals CTO Joseph Shulman sells $608,210 of stock - Investing.com
Rhythm Pharmaceuticals CTO Joseph Shulman sells $608,210 of stock By Investing.com - Investing.com India
Rhythm Pharmaceuticals (NASDAQ:RYTM) Insider Alastair Garfield Sells 7,763 Shares - MarketBeat
Insider Selling: Rhythm Pharmaceuticals (NASDAQ:RYTM) Insider Sells 5,079 Shares of Stock - MarketBeat
Rhythm Pharmaceuticals CSO Alastair Garfield sells $912,703 in stock - Investing.com
Rhythm (NASDAQ: RYTM) CTO sells 5,079 shares in 10b5-1 plan - Stock Titan
Rhythm Pharmaceuticals Eyes AHO Growth, Global IMCIVREE Expansion and Pipeline Catalysts - NewsBreak: Local News & Alerts
Rhythm Pharmaceuticals Announces Appointment Of Manher (Aj) Joshi As Chief Medical Officer - TradingView
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Exploring a 22.56% Potential Upside on Robust Analyst Confidence - DirectorsTalk Interviews
Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. – DUS:1RV - TradingView
Rhythm Pharmaceuticals(RYTM.US) Officer Sells US$8.9 Million in Common Stock - Moomoo
Rhythm Pharmaceuticals EVP Mazabraud sells $6.6m in stock By Investing.com - Investing.com Nigeria
Rhythm Pharmaceuticals EVP, Jennifer Lee, sells $8.9m in stock By Investing.com - Investing.com UK
Rhythm Pharmaceuticals EVP Jennifer Kayden Lee Executes Stock Options and Sells Shares Under 10b5-1 Plan - Kalkine Media
Rhythm Pharmaceuticals EVP Yann Mazabraud Executes Stock Option and Sells Shares Under Rule 10b5-1 Plan - Kalkine Media
Rhythm Pharmaceuticals (NASDAQ:RYTM) EVP Yann Mazabraud Sells 57,000 Shares - MarketBeat
Insider Selling: Rhythm Pharmaceuticals (NASDAQ:RYTM) EVP Sells 75,834 Shares of Stock - MarketBeat
Rhythm Pharmaceuticals Inc (RYTM) 財務データ
収益
当期純利益
現金流量
EPS
Rhythm Pharmaceuticals Inc (RYTM) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Meeker David P | President and CEO |
Sep 14 '26 |
Sale |
102.67 |
50,000 |
5,133,442 |
239,258 |
0.72%
1.29%
大文字化:
|
ボリューム (24 時間):